subscribes you to a channel that always contains that latest version of the Nix Packages collection.

A Nix channel is just a URL that points to a place that contains a set of Nix expressions and a manifest.

I can provide full 24h logs and a copy of /var/lib/docker/network/files/local-kv.db if you give me a private channel.

In the rolling-release model that most browsers follow these days the alpha -> beta -> stable cycle is short so the typical "alpha slowly gets more stable & when it gets stable enough we mark it as beta" model doesn't and cannot apply here.see more0

Also, since MS uses Canary/Dev/Beta, Beta has a concrete meaning and using that name to describe Dev would be misleading at best.

No; beta is a separate channel that we're still waiting for. Dev is another alpha, just updated a bit slower than Canary.

Most people think you build the product then you market it. Thinking in loops means you build the marketing into the product. The product doesn't precede the marketing. The product is the marketing.

Cross-channel conversion paths See the big picture. Understand the value of upper funnel ad clicks in multi-click, cross-channel journeys.

The content can be loaded by external applications which handle the content delivery to the client, meaning that the content can be (re-)used by multiple applications and channels (web, mobile app, audio guides, IOT).

Channels A Channel is a single component of a pixel's color. For a colored pixel in GIMP, these components are usually Red, Green, Blue and sometimes transparency (Alpha). For a Grayscale image, they are Gray and Alpha and for an Indexed color image, they are Indexed and Alpha. The entire rectangular array of any one of the color components for all of the pixels in an image is also referred to as a Channel. You can see these color channels with the Channels dialog.

Full Alpha channel support for working with transparency

Channel binding: Depending on the DH functions, it might be possible for a malicious party to engage in multiple sessions that derive the same shared secret key by setting public keys to invalid values that cause predictable DH output (as in the previous bullet). It might also be possible to set public keys to equivalent values that cause the same DH output for different inputs. This is why a higher-level protocol should use the handshake hash (h) for a unique channel binding, instead of ck, as explained in Section 11.2.

Thus it's an incomplete fix, and the correct solution is binding the transcript.

It's well-understood nowadays that channel binding must cover the session transcript.

Nimodipine controlled the escalation of the morphine dose in 9 patients (65%), and placebo in 4 (28%), the difference being statistically significant (P=0.03). The dose of morphine was reduced from 313±52 to 174±33 mg/day (P<0.001) in the nimodipine group, and from 254±26 to 218±19 mg/day (not significant) in the placebo group.

RAJ: Yes and no. Time does not function in the limited way in which you conceive it. I will go into that at another time. Suffice it to say that although you will perceive the communication as occurring simultaneously with your end of the conversation, my end of the conversation takes place when it is convenient for me. It is then slotted into your time reference at the appropriate moments.

RAJ: Yes and no. I am not speaking directly with you. I am, you might say, speaking to you in meanings without language. If I were to communicate with someone in India they would hear me in their language, and yet I would not be speaking to them in any language at all, just meanings. The more you become integrated with your experience through the technique you are now using, the more accurate will be your “translation” and the more easily it will flow. Right now, my meanings are flowing fluidly, but the fact that your typewriter is stuttering is due to your awkwardness and lack of experience in communication on this level of consciousness.

It is true that you are not participating in spiritualism. You are not communicating with a soul that has “passed on.” You are not speaking to an individuality still befuddled by the three-dimensional illusion of birth and death who thinks that he was ever born or ever died. I am not the medium through which the Christ-consciousness is revealing Itself as your conscious experience of Being. But, I do exist, as does every other individualization who has existed as an infinite aspect of Fourth-dimensional Conscious Being. There is infinite progression, even beyond the partial, three-dimensional-only view. It is simply ignorance—the inability to see infinitely—which would make one think that once the “mortal dream” is grown out of, there does not continue to be the infinite unfolding of Being as Conscious Being. This is true before or after the experience called death.

In fact, the more you can find your answers coming from that which you recognize to be your own Being, without any possibility of imagining that it is coming from someone or something separate from yourself—such as me—the better it will be for you in tying together those aspects of your Being which you have not consciously been aware of as Your Self. The fact is that it is all You. But, it must become your conscious experience of your Being, without any dichotomy of any kind.

It is clear from the use of ES2 and RMG-II cell lines that the Atlas Antibodies ARID1A antibody is specific for ARID1A in both Western blots and formalin-fixed paraffin embedded preparations of human origin and, coupled with the literature evidence, that it is validated in human tissue.

A No Primary antibody control (NPA) showed no staining in the epithelial or nuclear compartment (Figure 3B; Dataset e).

There was no cytoplasmic or extracellular stromal background staining present and the antibody titrated successfully losing the intensity of staining, as expected

Control slides, omitting the primary antibody, were negative except for the ER2 condition in the RMG-II cell pellet where a weak cytoplasmic background could be seen (Figure 2; Dataset d). Thus there was minimal background inherent in the staining procedure. It was therefore determined that the antibody showed specificity for formalin-fixed paraffin embedded tissues and could be run on murine tissue.

Using Western blot and IHC on murine wild-type and knockout tissue we have demonstrated that this antibody to ARID1A correctly stains murine tissue by immunohistochemistry.

It could be demonstrated that the HPA ARID1A antibody showed positive expression in ES-2 cell lines at the expected size of 270 kDa and no staining for RMG-II.

Patient groups, lastly, could write open letters to all companies and researchers withholding methods and results of trials on treatments taken by their members, represent their constituencies by holding individuals to reasonable account, and again help improve compliance.

This negates a key defence commonly cited by trialists and sponsors when facing calls for greater transparency: that journals reject “negative” results. All trials can now be reported, immediately, using clinicaltrials.gov as a first or last resort, if the trialist is willing. The question remains: how can we ensure this is done?

The Big Myth About Hotel Metasearch (Travel Tuesday)